Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2015 07:03 ET | Source: KemPharm

KemPharm, Inc. to Report Pharmacokinetic Data From Intranasal Human Abuse Liability Study on Second Quarter Conference Call

CORALVILLE, Iowa, Aug. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
August 06, 2015 17:20 ET | Source: KemPharm

KemPharm, Inc. to Report Q2 2015 Results

CORALVILLE, Iowa, Aug. 6, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
August 04, 2015 07:03 ET | Source: KemPharm

KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference

CORALVILLE, Iowa, Aug. 4, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
June 25, 2015 16:51 ET | Source: KemPharm

KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities

CORALVILLE, Iowa, June 25, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
June 11, 2015 07:03 ET | Source: KemPharm

KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP

CORALVILLE, Iowa, June 11, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
May 27, 2015 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports Q1 2015 Results

Recent Highlights: Completed pre-NDA meeting for KP201/APAP with FDA on May 20, 2015 Initial public offering closed on April 21, 2015 Appointed David M. Tierney to Board of Directors on...
May 21, 2015 09:03 ET | Source: KemPharm

KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP

CORALVILLE, Iowa, May 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
May 19, 2015 16:05 ET | Source: KemPharm

KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit

CORALVILLE, Iowa, May 19, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular...
May 18, 2015 16:02 ET | Source: KemPharm

KemPharm, Inc. to Report Q1 2015 Results

CORALVILLE, Iowa, May 18, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular...
April 15, 2015 21:11 ET | Source: KemPharm

KemPharm Announces Pricing of Initial Public Offering

CORALVILLE, Iowa, April 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity...